MMRV vaccine
| Combination of | |
|---|---|
| Measles vaccine | Vaccine |
| Mumps vaccine | Vaccine |
| Rubella vaccine | Vaccine |
| Varicella vaccine | Vaccine |
| Clinical data | |
| Trade names | ProQuad, Priorix Tetra |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
Subcutaneous, intramuscular | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
The MMRV vaccine combines the
varicella (chickenpox) vaccine
. The MMRV vaccine is typically given to children between one and two years of age.
Several companies supply MMRV vaccines. ProQuad is marketed by
Recommendations
The World Health Organization (WHO) recommends vaccinating against measles, mumps, rubella (German measles), and varicella (chickenpox) because the risks of these diseases far outweigh the risks of vaccinating against them. In particular, the World Health Organization recommends varicella vaccination in countries where the vaccine is affordable, the disease is a relatively important problem, and high and sustained vaccine coverage can be achieved. A few countries have widely implemented this. MMR and varicella vaccine are given at roughly the same time and a booster injection is recommended for both.[citation needed]
The MMRV vaccine, a combined MMR and varicella vaccine, simplifies administration of the vaccines.
Contraindications
- For individuals who are moderately or severely ill, it is generally recommended that they wait until after recovery before getting ProQuad. No such precautions are recommended for minor illnesses, such as a cold.[citation needed]
- It is recommended that aspirin or aspirin containing products be avoided for at least six weeks after receiving ProQuad vaccine (aspirin is not recommended in children under 16 in any case). A serious condition called Reye's syndromehas been reported in patients with chicken pox and influenza.
- Individuals should not receive ProQuad without first consulting their doctor if there is a history of a life-threatening allergic reaction to gelatin, eggs, the antibiotic neomycin, or a previous MMR or chicken pox vaccine.[citation needed]
Doctors are advised to be aware of whether or not a patient has HIV/AIDS or another disease that affects the immune system, is taking a medication that affects the immune system, has cancer, a fever or active untreated tuberculosis, is receiving cancer treatment, or has ever had a low platelet count (a blood disorder).[citation needed]
Adverse events
Rare but serious adverse events reported following ProQuad vaccination include
deafness; long-term seizures, coma, or lowered consciousness; seizures (jerking or staring) caused by fever; or temporary low platelet count.[11]
For children age two and younger, the MMRV vaccine is associated with significantly more
febrile seizures per 10,000 vaccinated children (95% CI 2.6–5.6), 7.5 additional mostly mild fever episodes per 100 vaccinated children (95% CI, 5.4–9.4) and 1.1 additional measles-like rash per 100 children (95% CI, 0.2–1.8). Febrile seizures caused by the MMRV vaccine occur 7 to 10 days after vaccination. In children age 4–6, there is no evidence for an increased risk in febrile seizures after the administration of Merck Proquad compared to the separate administration of MMR and Varicella vaccines.[12][13]
Legal status
Merck ProQuad was approved for medical use in the United States in September 2005,[14][15] in the European Union in April 2006,[3] and in Australia in February 2007.[16]
GSK Priorix Tetra was approved for medical use in Australia in November 2005.[17]
See also
References
- ^ a b "Measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine (ProQuad) Use During Pregnancy". Drugs.com. 16 October 2019. Retrieved 26 January 2020.
- ^ "DailyMed - PROQUAD- measles, mumps, rubella and varicella virus vaccine live injection, powder, lyophilized, for suspension".
- ^ a b "ProQuad EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 8 October 2020.
- S2CID 46973762.
- ^ "GlaxoSmithKline Clinical Trial Register". GlaxoSmithKline. Archived from the original on 30 November 2007. Retrieved 19 October 2019.
- ^ "Priorix-tetra". The Australian Immunisation Handbook. 4 June 2018. Archived from the original on 19 October 2019. Retrieved 18 October 2019.
- PMID 26251259.
- ^ "PEI Table of vaccines for measles with a valid marketing authorisation". PEI , Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (in German). 19 October 2019. Archived from the original on 19 October 2019. Retrieved 18 October 2019.
- S2CID 41981427.
- PMID 18340332.
- ^ a b "MMRV (Measles, Mumps, Rubella & Varicella) VIS". CDC. 21 May 2010. Archived from the original on 20 January 2015.
- PMID 20587679.
- ^ "CBER clinical review of studies submitted in support of licensure of ProQuad" (PDF). US Food and Drug Administration. August 2005.
- ^ "ProQuad". U.S. Food and Drug Administration (FDA). Archived from the original on 23 July 2017. Retrieved 8 October 2020.
- ^ "ProQuad". U.S. Food and Drug Administration (FDA). STN: 125108. Retrieved 8 October 2020.
- ^ "ProQuad measles, mumps, rubella, varicella live virus vaccine injection vial" (PDF). Therapeutic Goods Administration (TGA). Retrieved 8 October 2020.[permanent dead link]
- ^ "Priorix Tetra Vaccine 0.5mL powder for injection vial" (PDF). Therapeutic Goods Administration (TGA). Retrieved 8 October 2020.[permanent dead link]
Further reading
- Centers for Disease Control and Prevention (CDC) (December 2005). "Notice to Readers: Licensure of a Combined Live Attenuated Measles, Mumps, Rubella, and Varicella Vaccine" (PDF). MMWR Morb. Mortal. Wkly. Rep. 54 (47): 1212–14.
- Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q (November 2015). "Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety". Medicine. 94 (44): e1721. PMID 26554769.
- World Health Organization (January 2009). The immunological basis for immunization series: module 7: measles (update 2009). ISBN 9789241597555.
- World Health Organization (November 2010). The immunological basis for immunization series: module 16: mumps. ISBN 9789241500661.
- World Health Organization (December 2008). The immunological basis for immunization series: module 11: rubella. ISBN 9789241596848.
- World Health Organization (May 2008). The immunological basis for immunization series : Module 10: Varicella-zoster virus. ISBN 9789241596770.
- Ramsay M, ed. (December 2019). "Chapter 21: Measles". Immunisation against infectious disease. Public Health England.
- Ramsay M, ed. (April 2013). "Chapter 23: Mumps". Immunisation against infectious disease. Public Health England.
- Ramsay M, ed. (April 2013). "Chapter 28: Rubella". Immunisation against infectious disease. Public Health England.
- Ramsay M, ed. (March 2013). "Chapter 34: Varicella". Immunisation against infectious disease. Public Health England.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 13: Measles". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. ISBN 978-0990449119.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 15: Mumps". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. ISBN 978-0990449119.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 20: Rubella". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: U.S. ISBN 978-0990449119.
- Hamborsky J, Kroger A, Wolfe S, eds. (2015). "Chapter 22: Varicella". Epidemiology and Prevention of Vaccine-Preventable Diseases (13th ed.). Washington D.C.: ISBN 978-0990449119.
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 7: Measles". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 9: Mumps". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).
- Roush SW, Baldy LM, Hall MA, eds. (March 2019). "Chapter 14: Rubella". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: U.S. Centers for Disease Control and Prevention (CDC).
- Roush SW, Baldy LM, Hall MA, eds. (9 January 2020). "Chapter 17: Varicella". Manual for the surveillance of vaccine-preventable diseases. Atlanta GA: Centers for Disease Control and Prevention (CDC).
